Los puntos clave no están disponibles para este artículo en este momento.
The Panel recommended shared decision-making for men age 55 to 69 years considering PSA-based screening, a target age group for whom benefits may outweigh harms. Outside this age range, PSA-based screening as a routine could not be recommended based on the available evidence.
Carter et al. (Mon,) studied this question.